Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies
Published 2010 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume 50, Issue 12, Pages 1916-1930
Publisher
Informa UK Limited
Online
2010-06-18
DOI
10.3109/10428190903207548
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- GSK-3b inhibition: At the crossroad between Akt and mTOR constitutive activation to enhance cyclin D1 protein stability in mantle cell lymphoma
- (2011) Jessica Dal Col et al. CELL CYCLE
- Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance, and cancer therapy
- (2010) Andrew Y. Choo et al. CELL CYCLE
- Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia
- (2009) R. Crazzolara et al. BLOOD
- Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome
- (2009) David T. Teachey et al. BRITISH JOURNAL OF HAEMATOLOGY
- Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma
- (2009) Thomas M. Habermann et al. BRITISH JOURNAL OF HAEMATOLOGY
- Curcumin Disrupts the Mammalian Target of Rapamycin-Raptor Complex
- (2009) C. S. Beevers et al. CANCER RESEARCH
- A Phase I Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Deforolimus in Patients with Advanced Malignancies
- (2009) C. M. Hartford et al. CLINICAL CANCER RESEARCH
- mTOR Inhibitor RAD001 (Everolimus) Has Antiangiogenic/Vascular Properties Distinct from a VEGFR Tyrosine Kinase Inhibitor
- (2009) H. A. Lane et al. CLINICAL CANCER RESEARCH
- Phase III Study to Evaluate Temsirolimus Compared With Investigator's Choice Therapy for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
- (2009) Georg Hess et al. JOURNAL OF CLINICAL ONCOLOGY
- Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma
- (2009) E Drakos et al. LEUKEMIA
- Regulation of D-cyclin translation inhibition in myeloma cells treated with mammalian target of rapamycin inhibitors: rationale for combined treatment with extracellular signal-regulated kinase inhibitors and rapamycin
- (2009) P. Frost et al. MOLECULAR CANCER THERAPEUTICS
- A pilot trial of the mTOR (mammalian target of rapamycin) inhibitor RAD001 in patients with advanced B-CLL
- (2008) Thomas Decker et al. ANNALS OF HEMATOLOGY
- Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study
- (2008) A. Goy et al. ANNALS OF ONCOLOGY
- 69: Sirolimus (SRL)-Based GVHD Prophylaxis After TBI/TT/Cy Allogeneic HSCT in Pediatric Patients with HR All: Results of a Multi-Institutional Pilot Study
- (2008) M.A. Pulsipher et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma
- (2008) J. Dal Col et al. BLOOD
- Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004
- (2008) Yuhong Zhou et al. CANCER
- Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma
- (2008) Stephen M. Ansell et al. CANCER
- A Phase 2 Clinical Trial of Deforolimus (AP23573, MK-8669), a Novel Mammalian Target of Rapamycin Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies
- (2008) D. A. Rizzieri et al. CLINICAL CANCER RESEARCH
- The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma
- (2008) Philipp Baumann et al. EXPERIMENTAL CELL RESEARCH
- Temsirolimus downregulates p21 without altering cyclin D1 expression and induces autophagy and synergizes with vorinostat in mantle cell lymphoma
- (2008) Victor Y. Yazbeck et al. EXPERIMENTAL HEMATOLOGY
- Mammalian target of rapamycin (mTOR) pathway signalling in lymphomas
- (2008) Elias Drakos et al. EXPERT REVIEWS IN MOLECULAR MEDICINE
- Phase I Trial of the Novel Mammalian Target of Rapamycin Inhibitor Deforolimus (AP23573; MK-8669) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients With Advanced Malignancies
- (2008) Monica M. Mita et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
- (2008) Peter H. Wiernik et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Rapamycin shows anticancer activity in primary chronic lymphocytic leukemia cellsin vitro, as single agent and in drug combination
- (2008) Anna Åleskog et al. LEUKEMIA & LYMPHOMA
- Is mTOR inhibition a therapeutic option in chronic lymphocytic leukemia?
- (2008) Thomas Decker LEUKEMIA & LYMPHOMA
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started